{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:12:16Z","timestamp":1792059136388,"version":"4.4.0"},"reference-count":36,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,9,1]]},"abstract":"<jats:p>Objective. To investigate the clinical effectiveness of botulinum neurotoxin type A (BoNT) to reduce drooling in children with cerebral palsy (CP).<\/jats:p>\n               <jats:p>Methods. A controlled clinical trial was performed in which the results of single-dose BoNT injections in the submandibular glands were compared with treatment with scopolamine. Forty-five children who had CP and experienced severe drooling were enrolled. Drooling severity was measured at baseline, during application of scopolamine, and at different intervals after BoNT injections up to 24 weeks, using the Drooling Quotient (DQ), the Teacher Drooling Scale (TDS), and Visual Analog Scales (VAS).<\/jats:p>\n               <jats:p>Results. Drooling was reduced during scopolamine application as well as after BoNT injections. Compared with baseline, the mean DQ showed a significant decrease throughout the study. Greatest reductions were achieved 2 to 8 weeks after BoNT injection. No significant differences were found between scopolamine measurements and those up to 24 months after BoNT injection. Using VAS, parents recorded the effect on drooling in which significant differences were found between baseline VAS score and all follow-up assessments. According to our definition of \u201csuccess to therapy,\u201d demanding a 2-point decrease on the TDS, 61.5% of patients responded to BoNT injections. Analysis of the DQ demonstrated a response rate of 53% of the patients to scopolamine and 48.7% to BoNT until 24 weeks after BoNT injections, the actual duration of this study. As a reaction to scopolamine, 71.1% of the patients had moderate to severe side effects. Only nonsevere, incidental side effects were reported after BoNT injections.<\/jats:p>\n               <jats:p>Conclusions. During scopolamine application as well as after intraglandular BoNT injections, a clinically relevant reduction in drooling was achieved in children with CP, demonstrating maximum effect 2 to 8 weeks after injections. This is the first controlled clinical trial that confirmed a significant effect of BoNT injections in the treatment of drooling. General anesthesia was needed for all children. BoNT injections show fewer and less serious side effects than transdermal scopolamine treatment.<\/jats:p>","DOI":"10.1542\/peds.2003-1104-l","type":"journal-article","created":{"date-parts":[[2004,11,5]],"date-time":"2004-11-05T17:23:17Z","timestamp":1099675397000},"page":"620-627","source":"Crossref","is-referenced-by-count":170,"title":["Effect of Botulinum Toxin in the Treatment of Drooling: A Controlled Clinical Trial"],"prefix":"10.1542","volume":"114","author":[{"given":"Peter H.","family":"Jongerius","sequence":"first","affiliation":[{"name":"Department of Rehabilitation, University Medical Centre St Radboud, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.A. van den","family":"Hoogen","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, University Medical Centre St Radboud, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques van","family":"Limbeek","sequence":"additional","affiliation":[{"name":"Sint Maartenskliniek, Rehabilitation Centre, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fons J.","family":"Gabree\u0308ls","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, University Medical Centre St Radboud, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen van","family":"Hulst","sequence":"additional","affiliation":[{"name":"Department of Pediatric Neurology, University Medical Centre St Radboud, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Rotteveel","sequence":"additional","affiliation":[{"name":"Department of Pediatric Neurology, University Medical Centre St Radboud, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2004,9,1]]},"reference":[{"key":"2021121021561578300_R1","doi-asserted-by":"crossref","unstructured":"Ekedahl C. Surgical treatment of drooling. Acta Otolaryngol.\u20081974;77:215\u2013220","DOI":"10.3109\/00016487409124619"},{"key":"2021121021561578300_R2","unstructured":"Crysdale WS. Management options for the drooling patient. Ear Nose Throat J\u20081989;68:820, 825\u2013826, 829\u2013830"},{"key":"2021121021561578300_R3","doi-asserted-by":"crossref","unstructured":"Harris SR, Purdy AH. Drooling and its management in cerebral palsy. Dev Med Child Neurol.\u20081987;29:807\u2013811","DOI":"10.1111\/j.1469-8749.1987.tb08830.x"},{"key":"2021121021561578300_R4","doi-asserted-by":"crossref","unstructured":"Hussein I, Kershaw AE, Tahmassebi JF, Fayle SA. The management of drooling in children and patients with mental and physical disabilities: a literature review. Int J Paediatr Dent.\u20081998;8:3\u201311","DOI":"10.1046\/j.1365-263X.1998.00055.x"},{"key":"2021121021561578300_R5","doi-asserted-by":"crossref","unstructured":"Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C, Beuche W. Botulinum toxin to reduce saliva flow: selected indications for ultrasound-guided toxin application into salivary glands. Laryngoscope.\u20082002;112:82\u201386","DOI":"10.1097\/00005537-200201000-00015"},{"key":"2021121021561578300_R6","doi-asserted-by":"crossref","unstructured":"Jongerius PH, Rotteveel JJ, van den HF, Joosten F, van Hulst K, Gabreels FJ. Botulinum toxin A: a new option for treatment of drooling in children with cerebral palsy. Presentation of a case series. Eur J Pediatr.\u20082001;160:509\u2013512","DOI":"10.1007\/s004310100784"},{"key":"2021121021561578300_R7","doi-asserted-by":"crossref","unstructured":"Rapp D. Drool control: long-term follow-up. Dev Med Child Neurol.\u20081980;22:448\u2013453","DOI":"10.1111\/j.1469-8749.1980.tb04349.x"},{"key":"2021121021561578300_R8","doi-asserted-by":"crossref","unstructured":"Reddihough D, Johnson H, Staples M, Hudson I, Exarchos H. Use of benzhexol hydrochloride to control drooling of children with cerebral palsy. Dev Med Child Neurol.\u20081990;32:985\u2013989","DOI":"10.1111\/j.1469-8749.1990.tb08121.x"},{"key":"2021121021561578300_R9","doi-asserted-by":"crossref","unstructured":"Bothwell JE, Clarke K, Dooley JM, et al. Botulinum toxin A as a treatment for excessive drooling in children. Pediatr Neurol.\u20082002;27:18\u201322","DOI":"10.1016\/S0887-8994(02)00381-8"},{"key":"2021121021561578300_R10","doi-asserted-by":"crossref","unstructured":"Suskind DL, Tilton A. Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope.\u20082002;112:73\u201381","DOI":"10.1097\/00005537-200201000-00014"},{"key":"2021121021561578300_R11","doi-asserted-by":"crossref","unstructured":"Wong V, Sun JG, Wong W. Traditional Chinese medicine (tongue acupuncture) in children with drooling problems. Pediatr Neurol.\u20082001;25:47\u201354","DOI":"10.1016\/S0887-8994(01)00292-2"},{"key":"2021121021561578300_R12","doi-asserted-by":"crossref","unstructured":"Heine RG, Catto-Smith AG, Reddihough DS. Effect of antireflux medication on salivary drooling in children with cerebral palsy. Dev Med Child Neurol.\u20081996;38:1030\u20131036","DOI":"10.1111\/j.1469-8749.1996.tb15063.x"},{"key":"2021121021561578300_R13","doi-asserted-by":"crossref","unstructured":"Webb K, Reddihough DS, Johnson H, Bennett CS, Byrt T. Long-term outcome of saliva-control surgery. Dev Med Child Neurol.\u20081995;37:755\u2013762","DOI":"10.1111\/j.1469-8749.1995.tb12059.x"},{"key":"2021121021561578300_R14","unstructured":"Johnson H. An Exploratory Study on Drooling Using a Frequency Method of Measuring in a Naturalistic Setting (Thesis\/Dissertation). Melbourne, Australia: La Trobe University; 1990"},{"key":"2021121021561578300_R15","doi-asserted-by":"crossref","unstructured":"Camp-Bruno JA, Winsberg BG, Green-Parsons AR, Abrams JP. Efficacy of benztropine therapy for drooling. Dev Med Child Neurol.\u20081989;31:309\u2013319","DOI":"10.1111\/j.1469-8749.1989.tb04000.x"},{"key":"2021121021561578300_R16","unstructured":"Crossner CG. Salivary flow rate in children and adolescents. Swed Dent J.\u20081984;8:271\u2013276"},{"key":"2021121021561578300_R17","unstructured":"Heintze U, Birkhed D, Bjorn H. Secretion rate and buffer effect of resting and stimulated whole saliva as a function of age and sex. Swed Dent J.\u20081983;7:227\u2013238"},{"key":"2021121021561578300_R18","doi-asserted-by":"crossref","unstructured":"Kavanagh DA, O'Mullane DM, Smeeton N. Variation of salivary flow rate in adolescents. Arch Oral Biol.\u20081998;43:347\u2013352","DOI":"10.1016\/S0003-9969(98)00020-X"},{"key":"2021121021561578300_R19","doi-asserted-by":"crossref","unstructured":"Le Bell Y, Soderling E, Karjalainen S. Effect of repeated sampling and prestimulation on saliva buffer capacity and flow rate values in children. Scand J Dent Res.\u20081991;99:505\u2013509","DOI":"10.1111\/j.1600-0722.1991.tb01061.x"},{"key":"2021121021561578300_R20","doi-asserted-by":"crossref","unstructured":"Lenander-Lumikari M, Puhakka T, Makela MJ, Vilja P, Ruuskanen O, Tenovuo J. Effects of the common cold and intranasal fluticasone propionate treatment on mucosal host defense assessed by human saliva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.\u20081999;87:695\u2013699","DOI":"10.1016\/S1079-2104(99)70163-0"},{"key":"2021121021561578300_R21","doi-asserted-by":"crossref","unstructured":"Moret S, Coudert JL, Bejat C, Robin O, Lissac M. The influence of basal anxiety on unstimulated parotid and submandibular saliva. Arch Oral Biol.\u20081993;38:751\u2013754","DOI":"10.1016\/0003-9969(93)90070-3"},{"key":"2021121021561578300_R22","doi-asserted-by":"crossref","unstructured":"Burton MJ. The surgical management of drooling. Dev Med Child Neurol.\u20081991;33:1110\u20131116","DOI":"10.1111\/j.1469-8749.1991.tb14835.x"},{"key":"2021121021561578300_R23","doi-asserted-by":"crossref","unstructured":"Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C. Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies. J Oral Maxillofac Surg.\u20082003;61:454\u2013457","DOI":"10.1053\/joms.2003.50086"},{"key":"2021121021561578300_R24","doi-asserted-by":"crossref","unstructured":"Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ.\u20082001;323:596\u2013599","DOI":"10.1136\/bmj.323.7313.596"},{"key":"2021121021561578300_R25","doi-asserted-by":"crossref","unstructured":"Naumann M, Lowe NJ, Kumar CR, Hamm H. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol.\u20082003;139:731\u2013736","DOI":"10.1001\/archderm.139.6.731"},{"key":"2021121021561578300_R26","doi-asserted-by":"crossref","unstructured":"Blasco PA, Allaire JH. Drooling in the developmentally disabled: management practices and recommendations. Consortium on Drooling. Dev Med Child Neurol.\u20081992;34:849\u2013862","DOI":"10.1111\/j.1469-8749.1992.tb11382.x"},{"key":"2021121021561578300_R27","doi-asserted-by":"crossref","unstructured":"Bachrach SJ, Walter RS, Trzcinski K. Use of glycopyrrolate and other anticholinergic medications for sialorrhea in children with cerebral palsy. Clin Pediatr (Phila).\u20081998;37:485\u2013490","DOI":"10.1177\/000992289803700805"},{"key":"2021121021561578300_R28","doi-asserted-by":"crossref","unstructured":"Blasco PA, Stansbury JC. Glycopyrrolate treatment of chronic drooling. Arch Pediatr Adolesc Med.\u20081996;150:932\u2013935","DOI":"10.1001\/archpedi.1996.02170340046009"},{"key":"2021121021561578300_R29","doi-asserted-by":"crossref","unstructured":"Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord.\u20082002;17:1318\u20131320","DOI":"10.1002\/mds.10276"},{"key":"2021121021561578300_R30","doi-asserted-by":"crossref","unstructured":"Jongerius PH, van Tiel P, van Limbeek J, Gabreels FJ, Rotteveel JJ. A systematic review for evidence of efficacy of anticholinergic drugs to treat drooling. Arch Dis Child.\u20082003;88:911\u2013914","DOI":"10.1136\/adc.88.10.911"},{"key":"2021121021561578300_R31","doi-asserted-by":"crossref","unstructured":"Lewis DW, Fontana C, Mehallick LK, Everett Y. Transdermal scopolamine for reduction of drooling in developmentally delayed children. Dev Med Child Neurol.\u20081994;36:484\u2013486","DOI":"10.1111\/j.1469-8749.1994.tb11877.x"},{"key":"2021121021561578300_R32","doi-asserted-by":"crossref","unstructured":"Mier RJ, Bachrach SJ, Lakin RC, Barker T, Childs J, Moran M. Treatment of sialorrhea with glycopyrrolate: a double-blind, dose-ranging study. Arch Pediatr Adolesc Med.\u20082000;154:1214\u20131218","DOI":"10.1001\/archpedi.154.12.1214"},{"key":"2021121021561578300_R33","doi-asserted-by":"crossref","unstructured":"Neverlien PO, Sorumshagen L, Eriksen T, Grinna T, Kvalshaugen H, Lind AB. Glycopyrrolate treatment of drooling in an adult male patient with cerebral palsy. Clin Exp Pharmacol Physiol.\u20082000;27:320\u2013322","DOI":"10.1046\/j.1440-1681.2000.03099.x"},{"key":"2021121021561578300_R34","doi-asserted-by":"crossref","unstructured":"Siegel LK, Klingbeil MA. Control of drooling with transdermal scopolamine in a child with cerebral palsy. Dev Med Child Neurol.\u20081991;33:1013\u20131014","DOI":"10.1111\/j.1469-8749.1991.tb14818.x"},{"key":"2021121021561578300_R35","doi-asserted-by":"crossref","unstructured":"Jongerius PH, Joosten F, Hoogen FJ, Gabreels FJ, Rotteveel JJ. The treatment of drooling by ultrasound-guided intraglandular injections of botulinum toxin type A into the salivary glands. Laryngoscope.\u20082003;113:107\u2013111","DOI":"10.1097\/00005537-200301000-00020"},{"key":"2021121021561578300_R36","doi-asserted-by":"crossref","unstructured":"Porta M, Gamba M, Bertacchi G, Vaj P. Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry.\u20082001;70:538\u2013540","DOI":"10.1136\/jnnp.70.4.538"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/114\/3\/620\/1027703\/zpe00904000620.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/114\/3\/620\/1027703\/zpe00904000620.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T07:23:39Z","timestamp":1639207419000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/114\/3\/620\/67168\/Effect-of-Botulinum-Toxin-in-the-Treatment-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9,1]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2004,9,1]]},"published-print":{"date-parts":[[2004,9,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2003-1104-l","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9,1]]}}}